Prev·a·cid (pr v  -s d ) A trademark for the drug lansoprazole. |
lansoprazole
Prevacid, Prevacid I.V., Prevacid SoluTab, Prevpac, Zoton (UK)
Pharmacologic class: Gastric acid pump inhibitor
Therapeutic class: Antiulcer drug
Pregnancy risk category B
Action
Inhibits activity of proton pump in gastric parietal cells, decreasing gastric acid production
Availability
Capsules (delayed-release): 15 mg, 30 mg
Granules for oral suspension (delayed-release, enteric-coated): 15 mg, 30 mg
Powder for injection: 30 mg/vial
Prevpac (combination product for Helicobacter pylori infection): daily pack containing two 30-mg lansoprazole capsules, four 500-mg amoxicillin capsules, and two 500-mg clarithromycin tablets
Prevacid NapraPAC 375 (combination product for reducing risk of ulcers from nonsteroidal anti-inflammatory drugs [NSAIDs]): weekly pack containing seven 15-mg Prevacid capsules and fourteen 375-mg Naprosyn tablets
Prevacid NapraPAC 500 (combination product for reducing risk of ulcers from NSAIDs): weekly pack containing seven 15-mg Prevacid capsules and fourteen 500-mg Naprosyn tablets
Prevacid SoluTab (delayed-release, orally disintegrating tablet): 15 mg, 30 mg
⊘Indications and dosages
➣ Active duodenal ulcer
Adults: 15 mg P.O. daily for 4 weeks
➣H. pylori eradication, to reduce risk of duodenal ulcer recurrence
Adults: In triple therapy, 30 mg lansoprazole P.O., 1 g amoxicillin P.O., and 500 mg clarithromycin P.O. q 12 hours for 10 or 14 days. In dual therapy, 30 mg lansoprazole P.O. and 1 g amoxicillin P.O. q 8 hours for 14 days.
➣ Benign gastric ulcer
Adults: 30 mg P.O. daily for up to 8 weeks
➣ Gastric ulcer associated with NSAIDs
Adults: 30 mg P.O. once daily for up to 8 weeks
➣ To reduce risk of NSAID-associated gastric ulcer
Adults: 15 mg P.O. daily for up to 12 weeks
➣ Gastroesophageal reflux disease
Adults and children ages 12 to 17: 15 mg P.O. daily for up to 8 weeks
Children ages 1 to 11 weighing more than 30 kg (66 lb): 30 mg P.O. daily for up to 12 weeks
Children ages 1 to 11 weighing 30 kg (66 lb) or less: 15 mg P.O. daily for up to 12 weeks
➣ Erosive esophagitis
Adults and children ages 12 to 17: 30 mg P.O. daily for up to 8 weeks. Some patients may require 8 additional weeks.
Children ages 12 to 17: 30 mg P.O. daily for up to 8 weeks
Children ages 1 to 11 weighing more than 30 kg (66 lb): 30 mg P.O. daily for up to 12 weeks
Children ages 1 to 11 weighing 30 kg (66 lb) or less: 15 mg P.O. daily for up to 12 weeks
➣ Erosive esophagitis in patients who can't take drugs orally
Adults: 30 mg/day I.V. infused over 30 minutes for up to 7 days
➣ To maintain healing of erosive esophagitis
Adults: 15 mg P.O. daily
➣ Pathologic hypersecretory conditions (including Zollinger-Ellison syndrome)
Adults: Initially, 60 mg P.O. daily, to a maximum of 90 mg P.O. b.i.d. Divide daily dosages over 120 mg.
Dosage adjustment
• Significant hepatic insufficiency
Contraindications
• Hypersensitivity to drug or its components
Precautions
Use cautiously in:
• phenylketonuria (orally disintegrating tablets), severe hepatic impairment
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 18.
Administration
• To reconstitute for I.V. infusion, inject 5 ml of sterile water for injection into 30-mg vial; resulting solution contains 6 mg/ml. Mix gently until powder dissolves; then dilute reconstituted solution in 50 ml of 0.9% sodium chloride injection, lactated Ringer's injection, or 5% dextrose injection.
• Infuse I.V. dose over 30 minutes (using in-line filter provided) within 24 hours if reconstituted drug was diluted with 0.9% sodium chloride injection or lactated Ringer's injection, or over 12 hours if 5% dextrose injection was used.
• Don't give I.V. with other drugs or with diluents other than those listed above.
• Give oral form before meals.
• If patient has difficulty swallowing delayed-release capsule, open it and sprinkle contents onto small amount of soft food, such as applesauce or pudding. Don't crush or let patient chew drug.
• When giving orally disintegrating tablet, place tablet on patient's tongue and let it disintegrate until particles can be swallowed.
• Know that orally disintegrating tablet contains phenylalanine.
• When giving oral suspension, empty packet contents into container with 2 tbsp water. Stir contents well, and have patient drink immediately. Don't give oral suspension through nasogastric (NG) tube.
• When injecting contents of delayed-release capsule through NG tube, open capsule and mix granules with 40 ml apple juice. Then rinse tube with additional apple juice to clear.
| Route | Onset | Peak | Duration |
| P.O. | Rapid | Unknown | >24 hr |
Adverse reactions
CNS: headache, confusion, anxiety, malaise, paresthesia, abnormal thinking, depression, dizziness, syncope, cerebrovascular accident
CV: chest pain, hypertension, hypotension, myocardial infarction, shock
EENT: visual field deficits, otitis media, tinnitus, epistaxis
GI: nausea, diarrhea, abdominal pain, cholelithiasis, ulcerative colitis, esophageal ulcer, hematemesis, stomatitis, dysphagia, GI hemorrhage
GU: renal calculi, erectile dysfunction, abnormal menses, breast tenderness, gynecomastia
Hematologic: anemia
Respiratory: cough, bronchitis, asthma
Skin: urticaria, alopecia, acne, pruritus, photosensitivity
Interactions
Drug-drug. Drugs requiring acidic pH (such as ampicillin esters, digoxin, iron salts, itraconazole, ketoconazole): decreased absorption of these drugs
Sucralfate: decreased lansoprazole absorption
Theophylline: increased theophylline clearance
Drug-food. Any food: decreased rate and extent of GI drug absorption
Drug-herbs. Male fern: inactivation of herb
St. John's wort: increased risk of photosensitivity
Patient monitoring
• Monitor for GI adverse reactions.
• Assess nutritional status and fluid balance to identify significant problems.
Patient teaching
• Instruct patient to take before meals.
• If patient has difficulty swallowing, tell him to open delayed-release capsule and sprinkle contents onto small amount of soft food (such as applesauce or pudding). Emphasize that he must not crush or chew drug.
• Tell patient to take orally disintegrating tablet by placing it on tongue and letting it disintegrate.
• Instruct patient to take oral suspension by emptying packet contents into container with 2 tbsp water. Tell him to stir contents well and drink immediately.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.
Prevacid®
How to thank TFD for its existence? Tell a friend about us, add a link to this page, add the site to iGoogle, or visit webmaster's page for free fun content.
| ?Page tools | ||
|---|---|---|
|